Fiche société
Janssen Research & Development, LLC
Traitements, essais et publications liés.
Traitements18programmes
Essais8liés
Publications9liées
SourceDBlocale
Traitements
18| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AmivantamabThe purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Belgium, Brazil, Canada, China, France, Germany, … | À vérifier |
| EfgartigimodThe purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness). | Myasthénie | Phase 3 | United States, Israel, Switzerland | À vérifier | |
| JNJ-101556143 Formulation 1Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations. | Cancer | Phase 1/2 | À vérifier | United States, United Kingdom | À vérifier |
| JNJ-101556143 Formulation 2Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations. | Cancer | Phase 1/2 | À vérifier | United States, United Kingdom | À vérifier |
| JNJ-101556143 Formulation 3Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations. | Cancer | Phase 1/2 | À vérifier | United States, United Kingdom | À vérifier |
| NipocalimabThe purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs). | Lupus, Myasthénie | Phase 3 | United States, Israel, Switzerland | À vérifier | |
| Nipocalimab SC-LIVThe purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG. | Myasthénie | Phase 3 | À vérifier | United States, Australia, Belgium, Canada, China, Czechia, Denmark, France, … | À vérifier |
| PemetrexedThe goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment). | Cancer, Parkinson | Phase 3 | À vérifier | United States, Australia, Belgium, Brazil, Canada, China, France, Germany, … | À vérifier |
| PIPE-307 Dose AThis is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| PIPE-307 Dose BThis is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| PIPE-307 Dose AThis is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| NipocalimabThe purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs). | Lupus | Phase 3 | United States, Argentina, Australia, Brazil, Bulgaria, China, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Malaysia, Norway, Poland, … | À vérifier | |
| NipocalimabThe purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs). | Myasthénie | Phase 3 | United States, Israel, Switzerland | À vérifier | |
| NipocalimabThe purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs). | Myasthénie | Phase 2/3 | United States, Japan, Netherlands, Poland | À vérifier | |
| NipocalimabThe purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs). | Myasthénie | Phase 3 | United States, Australia, Belgium, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Mexico, Poland, South Korea, Spain, Sweden, Taiwan | À vérifier | |
| AmivantamabThe purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations. | Cancer | Phase 3 | Ralentissement de la progression | United States, Australia, Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Poland, Portugal, Puerto Rico, Russia, South Korea, … | À vérifier |
| JNJ-101556143 Formulation 1Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations. | Cancer | Phase 1/2 | À vérifier | United States, United Kingdom | À vérifier |
| EfgartigimodThe purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness). | Myasthénie | Phase 4 | France | À vérifier |
Essais cliniques
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Efgartigimod | Myasthénie | Phase 4 | NCT07072988 | OPTIMAGE — Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod | RECRUITING |
| JNJ-101556143 Formulation 1 | Cancer | Phase 1/2 | NCT06800313 | Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer | RECRUITING |
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | RECRUITING |
| Nipocalimab | Myasthénie | Phase 2/3 | NCT05265273 | A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | RECRUITING |
| Nipocalimab | Myasthénie | Phase 3 | NCT07217587 | EPIC — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | RECRUITING |
| Nipocalimab | Lupus | Phase 3 | NCT07438496 | GARDENIA-SLE — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | RECRUITING |
| PIPE-307 Dose A | SEP | Phase 2 | NCT06083753 | VISTA — Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis | COMPLETED |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Nipocalimab | Nipocalimab and other FcRn blockers in neuromuscular disorders. | Pharmacology & therapeutics | ||
| Nipocalimab | Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials. | Human vaccines & immunotherapeutics | ||
| Nipocalimab | Hospital resource utilization in patients with generalized myasthenia gravis treated with nipocalimab: results from the VIVACITY-MG3 study. | Journal of medical economics | ||
| Pemetrexed | Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands. | International immunopharmacology | ||
| Pemetrexed | Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. | Journal of medical economics | ||
| Pemetrexed | Implications of formulation change on the in-use stability of compounded pemetrexed infusion bags: Impact of excipients, solvent and storage conditions. | Journal of pharmaceutical and biomedical analysis | ||
| Nipocalimab | Pediatric Extrapolation in Neuropsychiatric Drug Development: Leveraging Pharmacokinetic and Pharmacodynamic Strategies to Facilitate FDA Approvals. | Clinical pharmacology and therapeutics | ||
| Pemetrexed | Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. | JAMA | ||
| Pemetrexed | Lack of resolution of inflammation marks malignant pleural mesothelioma progression. | Cancer drug resistance (Alhambra, Calif.) |